Transforming growth factor beta isoforms 1, 2, 3 (TGF-β1, 2, 3)

Transforming growth factor beta (TGF-β) isoforms 1, 2, and 3 are pleiotropic cytokines that regulate a wide array of biological processes, including cell proliferation, differentiation, and immune homeostasis (Wikipedia, 2024). They signal through a heterotetrameric complex of type I and type II serine/threonine kinase receptors, which in turn activate the canonical SMAD pathway to modulate gene expression (NIH, 2014). In the context of oncology, these isoforms exhibit a paradoxical role, acting as tumor suppressors in early stages but promoting metastasis, angiogenesis, and immune evasion in advanced disease (NIH, 2013). Furthermore, TGF-β is a primary driver of pathological fibrosis across multiple organs, including the lungs, liver, and heart, by stimulating excessive extracellular matrix production (Frontiers, 2020). Therapeutic targeting of these isoforms involves monoclonal antibodies, ligand traps, and antisense technologies, though clinical progress has been tempered by safety concerns such as cardiotoxicity and the development of skin lesions (Frontiers, 2020; NIH, 2020).

Other names

TGF-betaTGFBTransforming growth factor beta 1, 2, and 3TGF-beta 1/2/3

Ligand neutralization via monoclonal antibodies or decoy receptors (traps), inhibition of ligand expression via antisense oligonucleotides or vaccines.